AI English summary of an SEC filing — figures as filed

The company said director Karen Dahut resigned from the Board and all of its committees on May 1, 2025, effective May 8, 2025.

8-KDeparture or Appointment of Directors or Certain OfficersFiled May 2, 2025Period of report May 1, 2025Summary published (UTC) Oct 15, 2026

Key points

AI summary

The company said director Karen Dahut resigned from the Board and all of its committees on May 1, 2025, effective May 8, 2025.
The company said Ms. Dahut's resignation was not the result of any disagreement with her, the company, its management, the Board or any committee, or relate to any matter involving the company's operations, policies or practices.
Dexcom said director Karen Dahut resigned from the Board and from all of its committees, effective May 8, 2025. The company said the resignation was not the result of any disagreement with Dahut, the company, its management, the Board or any committee.
The company reported the resignation under Item 5.02 of Form 8-K, and the report was signed on May 2, 2025 by Executive Vice President and Chief Financial Officer Jereme M. Sylvain.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Director Karen Dahut Resigns from Board

The company said director Karen Dahut resigned from the Board and all of its committees on May 1, 2025, effective May 8, 2025.

Source · Based on the filing body and exhibits

Resignation Reason: No Disagreement

The company said Ms. Dahut's resignation was not the result of any disagreement with her, the company, its management, the Board or any committee, or relate to any matter involving the company's operations, policies or practices.

Source · Based on the filing body and exhibits

Resignation Scope: Board and All Committees

Dexcom said director Karen Dahut resigned from the Board and from all of its committees, effective May 8, 2025. The company said the resignation was not the result of any disagreement with Dahut, the company, its management, the Board or any committee.

Source · Based on the filing body and exhibits

Form 8-K Item 5.02 Filing and Signature

The company reported the resignation under Item 5.02 of Form 8-K, and the report was signed on May 2, 2025 by Executive Vice President and Chief Financial Officer Jereme M. Sylvain.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.